A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients

Status:
Completed

Trial end date:
2016-01-01

Target enrollment:

Participant gender:

This study is to evaluate the safety, appropriate dose, and efficacy of BIBF 1120 in liver cancer patients

Phase 2

Boehringer Ingelheim

Nintedanib
Sorafenib